Merck

Last updated January 31, 2026

124

Innovation Areas

5,362

Inventors

Collaborations

Substituted isoxazole tetrahydroisoquinoline scaffolds: MerckRecent Research Landscape

Metabolic instability in linear molecules leads to rapid drug clearance and poor efficacy. Engineering rigid bicyclic frameworks improves binding affinity and metabolic resistance to sustain therapeutic levels.

What technical problems is Merck addressing in Substituted isoxazole tetrahydroisoquinoline scaffolds?

Excessive hepatic triglyceride accumulation

(7)evidences

Abnormal lipid synthesis leads to metabolic disorders and liver dysfunction. Inhibiting the DGAT2 enzyme addresses the physiological failure of lipid homeostasis.

Inadequate glycemic control

(3)evidences

Pathological inability to maintain homeostatic blood sugar levels. Addressing this prevents chronic systemic complications and organ failure.

Peptide metabolic instability

(2)evidences

Insufficient metabolic regulation and poor insulin sensitivity. Resolving this enables effective treatment of type 2 diabetes and obesity.